MeSH D012514 - kaposi sarcoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Etoposide | Etoposide |  | 1994-02-10 |  |  |
| Paclitaxel | Paclitaxel |  | 2002-01-25 |  |  | |
| Etoposide | Toposar |  | 1995-02-27 |  |  | |
| Mylan | Etoposide | Etoposide |  | 2001-09-19 |  |  |
| Paclitaxel | Paclitaxel |  | 2002-01-25 |  |  | |
| Roche | Ribavirin, Peginterferon alfa-2a | Pegasys Copegus |  | 2004-06-04 |  |  |
| Interferon alfa-2a | Roferon-A |  | 1986-06-04 |  |  | |
| Sandoz | Paclitaxel | Paclitaxel |  | 2007-12-26 |  |  |
| Merck Sharp & Dohme | Interferon alfa-2b | Intron A |  | 1986-06-04 |  |  |
| Interferon alfa-2b | IntronA |  | 2000-03-09 |  |  | |
| Interferon alfa-2b | Viraferon |  | 2000-03-09 |  |  | |
| Eli Lilly | Vinblastine | Velban |  | 1982-01-01 |  |  |
| Alembic Pharmaceuticals | Paclitaxel | Paclitaxel |  | 2022-10-20 |  |  |
| Hospira | Etoposide | Etoposide |  | 1995-08-30 |  |  |
| Paclitaxel | Paclitaxel |  | 2002-05-08 |  |  | |
| Vinblastine | Vinblastine |  | 1987-08-18 |  |  | |
| Strides Pharma Global | Etoposide | Vepesid |  | 1986-12-30 |  |  |
| Bristol Myers Squibb | Paclitaxel | Abraxane | 2023-12-09 | 2005-01-07 | $982 M | Q2/23-Q1/24 |
| Etoposide | Etopophos |  | 1998-02-27 |  |  |
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
56%19/34
Phase 2
15%6/40
Phase 3
82%18/22
Approved: 13Overall Success rate: 7%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use